JAB-21822
- Generic Name
- JAB-21822
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
JAB-21822 is an oral small-molecule KRAS G12C inhibitor.
- Associated Conditions
- -
- Associated Therapies
- -
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 392
- Registration Number
- NCT06416410
- Locations
- 🇨🇳
Anhui Province cancer hospital, Hefei, Anhui, China
🇨🇳Pecking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, Beijing, China
A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT06162169
- Locations
- 🇨🇳
Beijing GoBroad Hospital, Beijing, Beijing, China
A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT06008288
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
A Food Effect Study of JAB-21822 in Healthy Subjects
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05875493
- Locations
- 🇨🇳
Beijing GoBroad Boren Hospital, Beijing, Beijing, China
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT05288205
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
- Conditions
- Interventions
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05194995
- Locations
- 🇨🇳
Research site31, Beijing, Beijing, China
🇨🇳Research site01, Beijing, Beijing, China
🇨🇳Research site02, Beijing, Beijing, China
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 311
- Registration Number
- NCT05009329
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.